Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > SBM mgmt, get on with it
View:
Post by lscfa on May 15, 2023 9:17pm

SBM mgmt, get on with it

An emerging trend in the skin lightening products market is the rising popularity of multi-functional products that offer multiple benefits such as sun protection, anti-aging, and skin brightening. Consumers are increasingly looking for products that offer more than just skin lightening benefits and provide additional skin care benefits as well.



https://www.accesswire.com/754878/Skin-Lightening-Products-Market-is-Estimated-to-Reach-US-379136-Million-at-a-CAGR-of-7-by-forecast-period-ending-2033-Data-by-Future-Market-Insights-Inc

Comment by MirrorWorldMan on May 16, 2023 12:25am
Yes. If people want to pay the price  for evidence based combination products and royalties remain. It's a win-win. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities